The secoiridoid profile of virgin olive oil conditions phenolic metabolism.

The European Food Safety Authority highlights the beneficial effects of olive oil phenols, mainly, secoiridoids. Nevertheless, the metabolism of secoiridoids in humans has not been fully elucidated. This research evaluated the metabolism of secoiridoids in humans after intake of olive oils with diverse phenolic profiles. For this purpose, three extra virgin olive oils (EVOOs) were ingested by six volunteers at scheduled meals, and urine samples were collected the following morning for subsequent LC-MS/MS analysis. Using untargeted analysis, urinary metabolites revealed representative patterns associated with the various olive oil phenolic contents in absolute and relative terms. We were able to identify metabolites obtained through phase I, phase II, and microbial metabolism with discrimination between tyrosol and hydroxytyrosol derivatives. Metabolism of phenols is differentially activated as a function of the olive oil secoiridoids content, and this proof-of-concept study shows how urinary metabolites represent olive oil phenolic content.

Omentin-1 and its relationship with inflammatory factors in maternal plasma and visceral adipose tissue of women with gestational diabetes mellitus.

PURPOSE: To investigate the association of omentin-1 and inflammatory factors in serum and visceral adipose tissue (VAT) of women with gestational diabetes mellitus (GDM) compared to normal pregnant (NP) subjects. Furthermore, to examine their correlation with maternal clinical characteristics. METHODS: We compared 116 GDM women to 115 NP women, at the time of cesarean section. Circulating omentin-1 and pro-inflammatory (IL-1ß, IL-6, TNF-α), and anti-inflammatory cytokines (IL-1RA, IL-10) were examined. Moreover, their mRNA expression in VAT, along with inflammatory factors involved in the NF-κB pathway (TLR2, TLR4, NF-κB, IKκB), were examined. RESULTS: Circulating omentin-1 (p = 0.022) was lower and circulating IL-1-ß, IL-1RA, as well as IL-10 (p = 0.005, p = 0.007, and p = 0.015, respectively), were higher in GDM compared to NP women. Omentin-1 correlated negatively with pre-pregnancy and gestational BMI, and HOMA-IR in all women, but was not associated with cytokines. TLR2, TLR4, IL-1ß, IL-1RA, IL-6, IL-10 mRNA expression in VAT was lower in GDM compared with controls (p < 0.05 all). In multivariate analysis, BMI at delivery was significantly correlated to omentin-1 concentrations in all and NP subjects. In addition, omentin-1 expression was correlated to inflammatory gene expression in all, GDM and NP, women (p < 0.05 all). CONCLUSION: Serum levels and VAT gene expression of omentin-1 are not independently linked to GDM; notwithstanding, GDM women have a VAT-altered inflammatory status. In addition, no systemic association between omentin-1 and inflammatory factors was found, whereas associations between their expression in all women were observed, indicating that expression of these adipokines is linked between them regardless of GDM.

Differential Expression of Inflammation-Related Genes in Down Syndrome Patients with or without Periodontal Disease.

AIM: Aware that Down Syndrome patients present among their clinical characteristics impaired immunity, the aim of this study is to identify the statistically significant differences in inflammation-related gene expression by comparing Down Syndrome patients with Periodontal Disease (DS+PD+) with Down Syndrome patients without Periodontal Disease (DS+PD-), and their relationship with periodontitis as a chronic oral inflammatory clinical feature. MATERIALS AND METHODS: Case study and controls on eleven Down Syndrome patients (DS+PD+ vs. DS+PD-). RNA was extracted from peripheral blood using a Qiagen PAXgene Blood miRNA Kit when performing an oral examination. A search for candidate genes (92 selected) was undertaken on the total genes obtained using a Scientific GeneChip® Scanner 3000 (Thermo Fisher Scientific) and Clariom S solutions for human, mouse, and rat chips, with more than 20,000 genes annotated for measuring expression levels. RESULTS: Of the 92 inflammation-related genes taken initially, four genes showed a differential expression across both groups with a p value of <0.05 from the data obtained using RNA processing of the patient sample. Said genes were TNFSF13B (p = 0.0448), ITGB2 (p = 0.0033), ANXA3 (p = 0.0479), and ANXA5 (p = 0.016). CONCLUSIONS: There are differences in inflammation-related gene expression in Down Syndrome patients when comparing patients who present a state of chronic oral inflammation with patients with negative rates of periodontal disease.

Carcinoma en coraza por cáncer de mama 17 años después / Carcinoma en cuirasse from breast cancer 17 years later

Resumen Caso clínico: paciente de 73 años de edad, con diagnóstico de adenocarcinoma ductal infiltrante en la mama izquierda. Se trató con mastectomía total, linfadenectomía axilar y quimioterapia. Diez años después le aparecieron un linfedema en el brazo izquierdo y hombro congelado. El linfedema estaba muy indurado y eritematoso, con numerosas lesiones costrosas y sobreinfectadas. La biopsia cutánea mostró infiltración neoplásica debida al carcinoma mamario y reporte de aumento de Ca 15.3. En el escáner cérvico-tóraco-abdomino-pélvico se observó derrame pleural izquierdo masivo, con atelectasia pulmonar subyacente y múltiples erosiones óseas, compatible con afectación tumoral. Tras recibir quimioterapia paliativa disminuyó temporalmente la infiltración cutánea tumoral. Conclusión: el carcinoma mamario es uno de principales cánceres que afectan a la mujer. Sus metástasis cutáneas son del orden de 37% a 5 años. El carcinoma en coraza es una variedad excepcional (3%), de evolución lenta, sin daño sistémico. Las pacientes con cáncer de mama deben tener un seguimiento estrecho postmastectomía y ante la sospecha de metástasis cutánea, diagnosticarla oportunamente para ofrecerles la opción del tratamiento temprano.

Abstract Clinical case: patient of 73 years of age, with diagnosis of infiltrating ductal adenocarcinoma in the left breast in 2004; it was treated with total mastectomy, axillary lymphadenectomy and chemotherapy; 10 years later, she had induration and erythema in the mastectomy area, with some superficial necrotic lesions and cutaneous infiltration to the right breast. In the left arm: indurated lymphedema, with numerous crusted, superficial and superinfected lesions. The skin biopsy showed neoplastic infiltration due to mammary carcinoma and an increase in Ca 15.3. In the cervico-thoraco-abdominal-pelvic scan, massive left pleural effusion was observed, with underlying pulmonary atelectasis and multiple bone erosions, compatible with tumor involvement. After receiving palliative chemotherapy, the cutaneous infiltration of the tumor decreased temporarily. Conclusion: mammary carcinoma is one of the main cancers that affect women. Their cutaneous metastases are of the order of 37% at 5 years. Cutaneous carcinoma is an exceptional variety (3%), of slow evolution, without systemic damage. Patients with breast cancer should have a close postmastectomy follow-up and, in case of skin metastasis suspicion, diagnose it in a timely manner to offer them the option of early treatment.

Cardiac metastasis from uterine leiomyosarcoma.

Cardiac metastases are more frequent than primary heart neoplasias. Nearly any malignant tumour may metastasize to the heart, but the most common are carcinomas rather than sarcomas. We report the case of a patient who presented with heart metastasis 6 years after resection of an uterine leiomyosarcoma. The patient died thirty months after surgical resection without evidence of cardiac recurrence. Although cardiac metastases from uterine leiomyosarcoma are exceptional, they should be suspected in the presence of suggestive symptoms, since they can be associated with long survival after surgical treatment.

Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.

Hyperlipidemia is common in type 2 diabetic patients and is an independent risk factor for cardiovascular disease. The aim of this trial was to evaluate the efficacy and safety of once-daily atorvastatin 10-80 mg for the treatment of hyperlipidemia in type 2 diabetics with plasma low-density lipoprotein cholesterol (LDL-C) levels exceeding 3.4 mmol/l (130 mg/dl). One hundred and two patients met the study criteria and received 10 mg/day atorvastatin. Patients who reached the target LDL-C level of

[Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia]. / Efecto de bezafibrato en la dieta de hipertensos con dislipidemia e hiperfibrinogenemia.

OBJECTIVE: To evaluate the fibrinogen and lipids response to diet plus bezafibrate in insulin-resistant patients with arterial hypertension and mixed hyperlipidemia. METHODS: A randomized double blind parallel design was used during a 90 days treatment period. Fibrinogen, lipids, insulin and peptide C assays as well as a glucose tolerance test were done at the start and end of treatment. The 28 patients received a hypolipemic diet low in refined sugars with bezafibrate added (400 mg/day) in 15 and a placebo in 13. RESULTS: The groups were similar in age, blood pressure and BMI. At the end of treatment, fibrinogen, cholesterol, triglycerides and LDL-C were lower in both groups as compared to the initial values, but only in the bezafibrate group there were: a) significant decrease in triglycerides (64 mg/dL, p 0.01); and b) marginal changes in fibrinogen (decreased 35 mg/dL, p = 0.09), total cholesterol (decreased 26 mg/dL, p = 0.10) and glucose/insulin ratio (increased from 4.4 to 5.2, p = 0.09). Bezafibrate lowered slightly the insulin level but did not affect peptide C. A correlation of changes in fibrinogen levels and the 60 min insulin concentration in the glucose tolerance test was higher in the bezafibrate group (r = 0.61) than in the placebo group (r = 0.23). CONCLUSIONS: In insulin resistant patients with high cardiovascular risk, bezafibrate and a placebo added to a hypolipemic diet decreased plasma fibrinogen. Bezafibrate lowered significantly the levels of triglycerides in these patients.

Diabetic ketoacidosis in adults: clinical and laboratory features.

In this retrospective study, we report the clinical and biochemical features of diabetic ketoacidosis (DKA) in adult patients who were managed at the Instituto Nacional de la Nutrición during a 6.5 year period. There were 98 episodes in 46 patients: 22 females (48%) and 24 males (52%). Six patients (13%) had four or more episodes of DKA. Thirty five percent of the events occurred in patients with IDDM; 48% in "late onset" NIDDM: 9% in "early onset" and 9% in classical NIDDM. Infections as the precipitating factor in 41% of episodes of DKA were the initial manifestation of diabetes. We compared our results with those from other reported series, finding no differences among them. The mean anion gap in our series was 30.4. Main complications identified were hypokalemia in five cases, hypoglycemia in four cases, hypernatremia in four cases, and acute pulmonary edema, ventricular fibrillation, neurological deficit and coma in one case each. There were three deaths (6.5%) in the whole group. To our knowledge, this is the largest series on adult patients with DKA reported in our country in the last decade. The obtained results may help evaluate prospectively the impact of different diagnostic and therapeutic strategies in the management of DKA.